Neutrogena T-Gel use with Merck's Propecia baldness drug recommended -- FDA cmte.
This article was originally published in The Rose Sheet
Executive Summary
NEUTROGENA T-GEL/MERCK PROPECIA CONCOMITANT USE RECOMMENDED FOR BALDNESS treatment by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee during the group's Nov. 13 review of the prescription oral hair regrowth drug finasteride. FDA had asked the committee to consider the effect of Neutrogena's OTC coal tar dandruff shampoo "on the assessment of the treatment response to Propecia." T-Gel was used in both the treatment and control groups of Merck's safety and efficacy trial for Propecia as a prophylaxis for seborrheic dermatitis. The recommended dose of T-Gel used during the trial was not specified.